<DOC>
	<DOC>NCT01342211</DOC>
	<brief_summary>This study will investigate the effect of PF-04950615, a new investigational lipid lowering agent, on LDL-C and other lipids.</brief_summary>
	<brief_title>A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>On a stable daily dose of atorvastatin, rosuvastatin or simvastatin. Lipids meet the following criteria at screening and prior to dosing: Fasting LDLC greater than 100 mg/dL and fasting TG less than 400 mg/dL History of a cardiovascular or cerebrovascular event or procedure during the past year. Poorly controlled type 1 or type 2 diabetes mellitus. Poorly controlled hypertension.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>PF-04950615</keyword>
	<keyword>RN316</keyword>
</DOC>